Warning: Taking hepatitis B drug with interferon potentially dangerous: Health Canada
	Loan $25 to change lives through Kiva.org
	Loan $25 to change lives through Kiva.org
	Hepatitis B hos børn i daginstitutioner
	Hepatitis B hos børn i daginstitutioner
	World Health Organization Urges Europe-Wide Hepatitis Plan
	Swiss drugmaker Novartis said on Thursday that Switzerland had approved its hepatitis B drug Sebivo, the medicine's first major approval.
	It's time for Britain to adopt universal hepatitis B immunisation
	Wealthy Chinese Warned of a Rising Rate in Hepatitis Diseases
	Milk Thistle for Alcoholic and/or Hepatitis B or C Liver Diseases:
	GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma
	All children in the UK should be immunised against potentially fatal liver disease caused by the hepatitis B virus, doctors' leaders have said.
	European consensus meeting draws up guidelines on HIV and hepatitis
	Pegylated Interferon Alfa-2b Effective for Chronic Hepatitis B
	Pegylated Interferon Alfa-2b Effective for Chronic Hepatitis B
	Lamivudine and High-dose Interferon Alfa Combination Therapy for Treatment-naive Children with Chronic Hepatitis B
	Major PEGASYS Trial in Chronic Hepatitis B Patients Published in New England Journal of Medicine
	Knowledge and attitudes to the introduction of hepatitis B vaccine in the children’s immunization programme
	Hepatitis Vaccination in Patients With Chronic Liver Disease
	Models to Predict Inflammation and Fibrosis in Patients with Chronic Hepatitis B
	After 144 Weeks of Adefovir Therapy in Chronic HBV Patients, Drug Resistance Emerges with Low Frequency
	Three Year Study of Adefovir Dipivoxil Demonstrates Sustained Efficacy in Presumed Precore Mutant Chronic Hepatitis B Patients
	Treatment of Chronic HBV Patients with Adefovir Monotherapy Results in Loss of HBsAg, Undetectable HBV DNA and Normalization of ALT
	The consequences of the introduction of hepatitis B vaccinations as one element of the children’s immunization program in Denmark
	Weight Loss and Exercise Improve Liver Disease
	Hepsera Reduces Lamivudine-Resistant HBV Levels in Liver Transplant Patients
	The Global Reduction in Hepatitis B Disease Burden from Vaccination
	Gilead Announces Preliminary Results from 48-Week Phase III Study of Emtricitabine in Patients with Chronic Hepatitis B
	Pegasys found superior to current hepatitis B treatments
	"Hepatitis respects no borders".
	Screening standards for infectious diseases in pregnancy
	Pegasys (peginterferon alfa-2a) Is More Effective Than Current Standard Therapy for Chronic Hepatitis B
	Prevalence of Hepatitis A, Hepatitis B and HIV Among Hepatitis C Positive State Hospital Patients
	No Link Between Hexavalent Vaccines and Child Deaths
	Significant Differences Found Regarding HBV Genotypes
	PEGASYS doubles the efficacy in difficult-to-treat hepatitis B virus versus conventional interferon
	EASL Consensus Statement on Hepatitis B
	Artificial human liver created
	HIV/HCV Co-infected Patients Are at Increased Risk of Hepatic Decompensation
	Early Epivir-HBV (lamivudine) Therapy May Prevent Liver Failure in Patients with Fulminant Hepatitis B
	Call for hepatitis B vaccination in UK
	New Vaccine Results In Up To Six Fewer Injections For Infants
	ADEFOVIR DIPIVOXIL (ADV) ALONE AND IN COMBINATION WITH LAMIVUDINE
	Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan.
	Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins.
	Low hepatitis B prevalence among pre-school children in Denmark: Saliva
	Frequency and load of hepatitis B virus DNA in first-time blood donors .........
	Living donor liver transplantation is feasible and safe
	Safe use of livers from donors with positive hepatitis B core antibody
	Study Finds Hepatitis B Drug Safe for Kids
	The Danish Hepatitis Association has learned that an international consensus conference on hepatitis B will take place in Geneva, Switzerland September 13-15, 2002.
	Gilead and GlaxoSmithKline Reach Marketing Agreement on Adefovir Dipivoxil
	EVIDENCE FOR THE EFFICACY OF PEGINTERFERON ALFA-2A (40 KD) (PEGASYS) IN THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B (CHB) AND IMPACT OF BASELINE FACTORS
	Adefovir Dipivoxil Improves Liver Histology and Reduces HBV Levels in Patients with Precore Mutant Chronic Hepatitis B
	Adefovir Dipivoxil Produces Significant Reductions in ALT and in HBV Levels in Patients with Lamivudine-Resistant HBV

<< Previous